Literature DB >> 237110

Vasoconstriction of the isolated rabbit ear artery caused by nicotinic agonists acting on adrenergic neurons.

O S Steinsland, R F Furchgott.   

Abstract

In the perfused isolated central ear artery of the rabbit, nicotine, acetylcholine (ACh), tetramethylammonium (TMA) and carbachol (CCh) at high concentrations (greater than 1 mug/ml) produced transient vasoconstriction. The order of potency was: nicotine greater than ACh greater than TMA greater than CCh. Over the concentration range used, all of the agonists except ACh gave bell-shaped log concentration-response curves. Methacholine did not cause vasoconstriction. The response to ACh, TMA or CCh, but not to nicotine, was potentiated by atropine (0.1-1.0 mug/ml). Tetraethylammonium, hexamethonium, mecamylamine and d-tubocurarine blocked the response to the nicotinic agonists and to nerve stimulation. Ear arteries from reserpine-treated rabbits gave no, or very little, constrictor response to the nicotinic agonists or to nerve stimulation. These findings support the conclusion that the vasoconstriction produced by the nicotinic agonists is mediated by norepinephrine released from adrenergic nerve terminals as a result of the action of the agents on neuronal nicotinic receptors located at or near the terminals. The potentiation by atropine of the constrictor response to ACh, TMA and CCh is attributed to the blockade by atropine of neuronal muscarinic receptors on which these agonists act to inhibit the release of norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 237110

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Role of primary sensory neurons in the central effects of nicotine.

Authors:  M Hajós; G Engberg
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Possible explanations for the antagonism by nicotine against reserpine-induced depletion of monoamines in mouse brain.

Authors:  R Oishi; K Suemaru; K Furuno; Y Gomita; K Saeki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

3.  The selective antimuscarinic action of stercuronium.

Authors:  C K Li; F Mitchelson
Journal:  Br J Pharmacol       Date:  1980-10       Impact factor: 8.739

4.  The interaction of McN-A-343 with pirenzepine and other selective muscarine receptor antagonists at a prejunctional muscarine receptor.

Authors:  L K Choo; F Mitchelson; Y M Vong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

5.  Prejunctional muscarine receptors in the rabbit ear artery differ from M1, M2 and M3 muscarine receptors.

Authors:  S A Darroch; L K Choo; F Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

6.  The effect of some antidepressants on prejunctional muscarinic receptors on the sympathetic nerves of the isolated rabbit ear artery.

Authors:  Y H Kwok; F Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

7.  Adrenergic and purinergic cotransmission in nicotine-evoked vasoconstriction in rabbit ileocolic arteries.

Authors:  R Bültmann; I von Kügelgen; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

8.  Succinylcholine, cholinoceptors and catecholamines: proposed mechanism of early adverse haemodynamic reactions.

Authors:  V Nigrovic
Journal:  Can Anaesth Soc J       Date:  1984-07

9.  Studies on the possible contribution of a peripheral presynaptic action of clonidine and dopamine to their vascular effects under in vivo conditions.

Authors:  G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

10.  Interaction of some muscarinic agonists and antagonists at the prejunctional muscarinic receptor in the rabbit ear artery preparation.

Authors:  L K Choo; F Mitchelson; Y M Vong
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.